Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Expert Review of Vaccines, published by Taylor & Francis Ltd, is a pivotal open access journal that has established itself as a leading source of peer-reviewed articles focusing on vaccine research, development, and policy. With an impressive categorization in the top quartile (Q1) across various domains including Drug Discovery, Immunology, Molecular Medicine, and Pharmacology for 2023, this journal plays a crucial role in disseminating high-quality scientific findings that drive advances in the field. Located in the United Kingdom, it serves a global audience of researchers, healthcare professionals, and students seeking to stay abreast of cutting-edge developments in vaccination strategies and technologies. The journal’s Scopus ranks further attest to its excellence, boasting remarkable placements in Pharmacology and Drug Discovery, reflecting its impact and reach. Since transitioning to an open access format in 2023, the journal has enhanced accessibility to vital research, empowering a broader audience to contribute to and engage with the discourse surrounding vaccines. As the field of immunization continues to evolve, Expert Review of Vaccines remains a cornerstone for those committed to advancing knowledge and practice in this essential area of health science.

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

MICROBIOLOGY AND IMMUNOLOGY, an esteemed journal published by WILEY, serves as a vital resource for researchers and professionals in the fields of microbiology, immunology, and virology. With its ISSN 0385-5600 and E-ISSN 1348-0421, this journal has been a cornerstone in scientific literature since its inception in 1977, bridging decades of research and innovation through its comprehensive coverage of emerging trends and discoveries. Although this journal operates without open access, it maintains a commendable presence in academic circles, reflected in its 2023 Quartile rankings of Q3 across the categories of Immunology, Microbiology, and Virology. As part of an important discourse in these disciplines, MICROBIOLOGY AND IMMUNOLOGY ensures its scholarly contributions are relevant to both seasoned researchers and emerging scholars. Positioned in a competitive journal landscape, with Scopus ranks indicating a median percentile across its fields, it remains committed to advancing knowledge through peer-reviewed articles, thereby supporting the continuous evolution of its focus areas. The journal's current scope encompasses topics critical for understanding pathogen-host interactions and the immune response, making it a crucial publication for any academic library or individual scholar dedicated to the biological sciences.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.